Free: Top Stocks for the $15 Trillion AI Revolution
AI is already transforming the world as we know it -- and this emerging technology will make some investors rich.

Discover 5 ways you can capitalize.

Download the report free today.
Alonzo  Weems net worth and biography

Alonzo Weems Biography and Net Worth

Alonzo Weems is senior vice president, enterprise risk management and chief ethics and compliance officer of Eli Lilly and Company. He leads Lilly’s global ethics and compliance function. 

Since joining Lilly as an attorney in 1997, Alonzo has held a variety of roles providing strategic legal counsel across different areas of the business ranging from oncology clinical development and global health outcomes to commercialization of products in multiple therapeutic areas. His prior leadership roles include vice president and deputy general counsel for corporate legal functions, general counsel for Lilly USA and general counsel for biomedicines and diabetes. In his role as general counsel for the global biomedicines and diabetes businesses, Alonzo led the legal teams in Australia, Canada, Europe, Japan and China, Lilly’s largest markets outside of the United States. Prior to becoming general counsel for Lilly USA, he served as general counsel and corporate secretary for Lilly Canada. From 2006-2008, Alonzo oversaw the refresh of the company’s workforce diversity and inclusion strategy in his role as director for global workforce diversity.

He earned a Bachelor of Arts degree from Wabash College and a J.D. from the Indiana University Maurer School of Law.  

Alonzo serves on the board of visitors for the IU Maurer School of Law and the boards of directors for the International School of Indiana and Early Learning Indiana. He is a member of the Chief Ethics and Compliance Officer Steering Committee for the International Federation of Pharmaceutical Manufacturers & Associations, a past president and member of the Indiana Board of Law Examiners and a past member of the law section executive committee for the Pharmaceutical Research and Manufacturers of America. 

What is Alonzo Weems' net worth?

The estimated net worth of Alonzo Weems is at least $4.27 million as of September 12th, 2023. Mr. Weems owns 7,760 shares of Eli Lilly and Company stock worth more than $4,269,009 as of September 22nd. This net worth evaluation does not reflect any other assets that Mr. Weems may own. Learn More about Alonzo Weems' net worth.

How old is Alonzo Weems?

Mr. Weems is currently 52 years old. There are 7 older executives and no younger executives at Eli Lilly and Company. The oldest executive at Eli Lilly and Company is Ms. Leigh Ann Pusey, Exec. VP of Corp. Affairs & Communications, who is 60 years old. Learn More on Alonzo Weems' age.

How do I contact Alonzo Weems?

The corporate mailing address for Mr. Weems and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Alonzo Weems' contact information.

Has Alonzo Weems been buying or selling shares of Eli Lilly and Company?

During the last ninety days, Alonzo Weems has sold $678,445.04 in shares of Eli Lilly and Company stock. Most recently, Alonzo Weems sold 1,148 shares of the business's stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a transaction totalling $678,445.04. Following the completion of the sale, the executive vice president now directly owns 7,760 shares of the company's stock, valued at $4,586,004.80. Learn More on Alonzo Weems' trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, Eli Lilly and Company insiders bought shares 1 times. They purchased a total of 29,992,668 shares worth more than $374,908,350.00. In the last year, insiders at the sold shares 41 times. They sold a total of 2,974,300 shares worth more than $21,822,710,171.39. The most recent insider tranaction occured on September, 12th when EVP Alonzo Weems sold 1,148 shares worth more than $678,445.04. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 9/12/2023.

Alonzo Weems Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/12/2023Sell1,148$590.98$678,445.047,760View SEC Filing Icon  
10/10/2022Sell656$326.23$214,006.886,950View SEC Filing Icon  
8/10/2022Sell656$304.50$199,752.008,136View SEC Filing Icon  
See Full Table

Alonzo Weems Buying and Selling Activity at Eli Lilly and Company

This chart shows Alonzo Weems's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $554.84
Low: $547.63
High: $555.15

50 Day Range

MA: $522.52
Low: $447.14
High: $599.54

2 Week Range

Now: $554.84
Low: $304.88
High: $601.84


950,065 shs

Average Volume

3,020,102 shs

Market Capitalization

$526.70 billion

P/E Ratio


Dividend Yield



Space CEO Featured on Good Morning America
A $25 Billion Earth Observation Market by 2040. Learn more
Continue Reading